, Volume 61, Issue 3, pp 419–427 | Cite as

Drug Treatment of Scleroderma

Therapy in Practice


Scleroderma or systemic sclerosis is a rare condition with many clinical manifestations including Raynaud’s phenomenon. As with many other rarely encountered diseases, drug therapy for scleroderma is often empirical with little evidence in the form of randomised controlled trials to aid drug choice.

Raynaud’s phenomenon has been recognised for well over 100 years. A considerable number of clinical trials in this area have demonstrated unequivocally the use of nifedipine as a gold standard. Large studies have also demonstrated the efficacy of iloprost. However, this drug is not as yet licensed for scleroderma in the UK or elsewhere. This presents an additional problem as information regarding the use and administration of unlicensed drugs is often sparse and post-marketing surveillance to assess safety is not routinely performed.

When looking at the other distinct conditions encountered by a patient with scleroderma it becomes evident that trials are often retrospective or limited in patient numbers. Studies investigating the use of methotrexate, antithymocyte globulin and cyclophosphamide in patients with scleroderma have been very small and in some cases not well designed. The major work on penicillamine was a retrospective trial. Again these drugs are not licensed for use in scleroderma.

Drug therapy for pulmonary hypertension secondary to scleroderma closely follows that outlined for primary pulmonary hypertension. In the US there is a patient registry for primary pulmonary hypertension that has enabled well designed, large-scale studies to demonstrate the benefits of epoprostenol in severe primary pulmonary hypertension. Hence, research in this area has progressed considerably over the last decade.

Clearly, a considerable amount of work is being carried out to elucidate new treatment regimens for scleroderma, however, evaluation of these studies is proving to be a difficult process. Designated hospital centres for scleroderma (there are currently 2 in the UK), better markers of disease activity and methods to measure improvement or deterioration in affected organs, should enable research into aetiology, disease progression and treatment to be carried out on a larger scale resulting, hopefully, in more conclusive answers.


  1. 1.
    Isenberg DA, Black C. ABC of rheumatology: Raynaud’s phenomenon, scleroderma and overlap syndromes. BMJ 1995; 310(6982): 795–8PubMedCrossRefGoogle Scholar
  2. 2.
    Black CM, Denton CP. The management of systemic sclerosis. Br J Rheumatol 1995; 34(1): 3–7PubMedCrossRefGoogle Scholar
  3. 3.
    Korn JH. Immunologic aspects of scleroderma. Curr Opin Rheumatol 1991; 3(6): 947–52PubMedCrossRefGoogle Scholar
  4. 4.
    Lee P, Langevitz P, Alderdice CA, et al. Mortality in systemic sclerosis (scleroderma). Q JMed 1992: 82(298): 139–48Google Scholar
  5. 5.
    Maricq HR, Weinrich MC, Keil JE, et al. Prevalence of Raynaud’s phenomenon in the general population: a preliminary study by questionnaire. J Chronic Dis 1986; 39(6): 423–7PubMedCrossRefGoogle Scholar
  6. 6.
    Porter JM, Bardana Jr EJ, Baur GM, et al. The clinical significance of Raynaud’s syndrome. Surgery 1976; 80(6): 756–64PubMedGoogle Scholar
  7. 7.
    Belch JJ, Ho M. Phannacotherapy of Raynaud’s phenomenon. Drags 1996; 52(5): 682–95CrossRefGoogle Scholar
  8. 8.
    Kahan A, Amor B, Menkes CJ, et al. Arandomised double-blind trial of diltiazem in the treatment of Raynaud’s phenomenon. Ann Rheum Dis 1985; 44(1): 30–3PubMedCrossRefGoogle Scholar
  9. 9.
    Kinney EL, Nicholas GG, Gallo J, et al. The treatment of severe Raynaud’s phenomenon with verapamil. J Clin Pharmacol 1982; 22(1): 74–6PubMedGoogle Scholar
  10. 10.
    Herrick AL, Gush RJ, Tully M, et al. A controlled trial of the effect of topical glyceryl trinitrate on skin blood flow and skin elasticity in scleroderma [letter]. Ann Rheum Dis 1994; 53(3): 2120CrossRefGoogle Scholar
  11. 11.
    Coffman JD, Clement DL, Creager MA, et al. International study of ketanserin in Raynaud’s phenomenon. Am J Med 1989; 87(3): 264–8PubMedCrossRefGoogle Scholar
  12. 12.
    Pope J, Fenlon D, Thompson A, et al. Ketanserin for Raynaud’s phenomenon in progressive systemic sclerosis [computer file]. Cochrane Database of Systemic Reviews 2000; 2: CD000954Google Scholar
  13. 13.
    Pancera P, Sansona S, Secchi S, et al. The effects of thromboxane A2 inhibition (picotamide) and angiotensin II blockade (losartan) in primary Raynaud’s phenomenon. J Int Med 1997; 242(5): 373–6CrossRefGoogle Scholar
  14. 14.
    Lau CS, McLaren M, Saniabadi A, et al. The pharmacological effects of cicaprost, an oral prostacyclin analogue, in patients with Raynaud’s syndrome secondary to systemic sclerosis — a preliminary study. Clin Exp Rheumatol 1991; 9(3): 271–3PubMedGoogle Scholar
  15. 15.
    Murai C, Sasaki T, Osaki H, et al. Oraliloprost for Raynaud’s phenomenon [letter]. Lancet 1989; II: (8673) 1218CrossRefGoogle Scholar
  16. 16.
    Sjogren RW. Gastrointestinal features of scleroderma. Curr Opin Rheumatol 1996; 8(6): 569–75PubMedCrossRefGoogle Scholar
  17. 17.
    Silver RM, Warrick JH, Kinsella MB, et al. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis with interstitial lung disease. J Rheumatol 1993; 20: (5) 838–44PubMedGoogle Scholar
  18. 18.
    Davas EM, Peppas C, Maragou M, et al. Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma. Clin Rheumatol 1999; 18(6): 455–61PubMedCrossRefGoogle Scholar
  19. 19.
    Rich S, Kaufmann E, Levy PS, et al. The effect of high doses of calcium channel-blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327(2): 76–81PubMedCrossRefGoogle Scholar
  20. 20.
    D’Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991; 115(5): 343–9PubMedGoogle Scholar
  21. 21.
    Alpert MA, Pressly TA, Mukerji V, et al. Short- and long-term hemodynamic effects of captopril in patients with pulmonary hypertension and selected connective tissue disease. Chest 1992; 102(5): 1407–12PubMedCrossRefGoogle Scholar
  22. 22.
    Ozawa T, Ninomiya Y, Honma T, et al. Increased serum angiotensin I converting enzyme activity in patients with mixed connective tissue disease and pulmonary hypertension. Scand J Rheumatol 1995; 24(1): 38–43PubMedCrossRefGoogle Scholar
  23. 23.
    Wigley FM, Wise RA, Scibold JR, et al. Intravenous iloprost in patients with Raynaud’s phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, double-blind study. Ann Intern Med 1994; 120(3): 199–206PubMedGoogle Scholar
  24. 24.
    Barst RJ, Rubin LJ, Long WA, et al. Acomparison of continuous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension: the primary pulmonary hypertension study group. N Engl J Med 1996; 334(5): 296–302PubMedCrossRefGoogle Scholar
  25. 25.
    Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): results of a randomised trial. Ann Intern Med 1990; 112(7): 485–91PubMedGoogle Scholar
  26. 26.
    Jones DK, Higenbottom TW, Wallwork J, et al. Treatment of primary pulmonary hypertension with intravenous epoprostenol (prostacyclin). Br Heart J 1987; 57(3): 270–8PubMedCrossRefGoogle Scholar
  27. 27.
    de la Mata J, Gomez-Sanchez MA, Aranzana M, et al. Long-term iloprost infusion therapy for severe pulmonary hypertension in patients with connective tissue diseases. Arthritis Rheum 1994; 37(10): 1528–33PubMedCrossRefGoogle Scholar
  28. 28.
    Wimalawansa S J. Calcitonin gene-related peptide and its receptors: molecular genetics, physiology, pathophysiology and therapeutic potentials. Endocr Rev 1996: 17(5): 533–85PubMedGoogle Scholar
  29. 29.
    Bunker CB, Reavley C, O’Shaughnessy DJ, et al. Calcitonin gene-related peptide in treatment of severe peripheral vascular insufficiency in Raynaud’s phenomenon. Lancet 1993; 342(8863): 80–3PubMedCrossRefGoogle Scholar
  30. 30.
    Shawket S, Dickerson C, Hazleman B, et al. Prolonged effect of CGRP in Raynaud’s patients: a double-blind randomised comparison with prostacyclin. Br J Clin Pharmacol 1991; 32(2): 209–13PubMedCrossRefGoogle Scholar
  31. 31.
    Tarkowski A, Lindgren I. Beneficial effects of antithymocyte globulin in severe cases of progressive systemic sclerosis. Transplant Proc 1994; 26(6): 3197–9PubMedGoogle Scholar
  32. 32.
    Matteson EL, Shbeeb MI, McCarthy TG, et al. Pilot study of antithymocyte globulin in systemic sclerosis. Arthritis Rheum 1996; 39(7): 1132–7PubMedCrossRefGoogle Scholar
  33. 33.
    Akesson A, Scheja A, Lundin A, et al. Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum 1994; 37(5): 729–35PubMedCrossRefGoogle Scholar
  34. 34.
    Akesson A, Wollheim FA, Thysell H, et al. Visceral improvement following combined plasmapheresis and immunosup-pressive drug therapy in progressive systemic sclerosis. Scand J Rheumatol 1988; 17(5): 313–23PubMedCrossRefGoogle Scholar
  35. 35.
    van den Hoogen FH, Boerbooms AM, Swaak AJ, et al. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomised double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 1996; 35(4): 364–72PubMedCrossRefGoogle Scholar
  36. 36.
    Appelboom T, Itzkowitch D. Cyclosporin in successful control of rapidly progressive scleroderma. JAMA 1987; 82(4): 866–7Google Scholar
  37. 37.
    Denton CP, Sweny P, Abdulla A, et al. Acute renal failure occurring in scleroderma treated with cyclosporin A: a report of three cases. Br J Rheumatol 1994; 33(1): 90–2PubMedCrossRefGoogle Scholar
  38. 38.
    Steen VD, Conte C, Owens GR, et al. Case control study of corticosteroid use prior to scleroderma renal crisis [abstract]. Arthritis Rheum 1994; 37 Suppl.: 360AGoogle Scholar
  39. 39.
    Steen VD, Medsger TA, Rodnan GP, et al. D-penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis. Ann Intern Med 1982; 97(5): 652–9PubMedGoogle Scholar
  40. 40.
    Clements PJ, Furst DE, Wong WK, et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two year, double-blind, randomised, controlled clinical trial. Arthritis Rheum 1999; 42(6): 1194–203PubMedCrossRefGoogle Scholar
  41. 41.
    Scibold JR, Kom JH, Simms R, et al. Recombinant human relaxin in the treatment of scleroderma: a randomised, double-blind, placebo-controlled trial. Ann Intern Med 2000; 132(11): 871–9Google Scholar
  42. 42.
    Clements PJ, Furst DE. Choosing appropriate patients with systemic sclerosis for treatment by autologous stem cell transplantation. J Rheumatol 1997; 48: 85–8Google Scholar

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  1. 1.Pharmacy DepartmentRoyal Free HospitalLondonEngland

Personalised recommendations